Design of Clinical Trials for Anti-Angiogenics

摘要: The development of new treatment programs is fraught frequently with similar conundrums. backbone the Hippocratic Oath, “First do no harm,” counsels clinical investigator to discover safest mode, schedule, and dose for administration. requirement treat disease drives identification optimal trial endpoints, analytic approaches. These same questions must be satisfied in order bring interventions general community whether pathology systemic, such as diabetes cancer, or focal, seen epilepsy appendicitis. are which discipline angiotherapy now faced. following issues will discussed context anti-angiogenic agents cancer paradigm.